Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02227303 · ClinicalTrials.gov registry record · NA

A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes

A NA study of Type 2 Diabetes Mellitus, sponsored by Medidata Solutions.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT02227303: Completed NA study of Type 2 Diabetes Mellitus, sponsored by Medidata Solutions.

NCT02227303 is a NA study of Type 2 Diabetes Mellitus that has completed, run by Medidata Solutions. The registered enrollment target is 23 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02227303, a NA study of Type 2 Diabetes Mellitus, has completed, sponsored by Medidata Solutions.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to explore the effect of 8-weeks use of the Medidata Patient Cloud (a mobile application for capturing data directly from subjects, enabling entry of diary and quality of life data into internet-enabled devices) in combination with an activity tracker (Fitbit Flex) on health outcomes in overweight people with Type 2 Diabetes.

Conditions Studied

Interventions

  • BEHAVIORAL lifestyle modification instructional and motivational sessions

Study Locations (1)

Florida

  • Miami Research Associates (MRA) - Miami

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2014-08
Est. Completion 2015-03
Phase NA
Medidata Solutions

1 total trials

What the finished NCT02227303 record still lists

NCT02227303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which lifestyle modification instructional and motivational sessions is the first listed.

NCT02227303 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT02227303 about?

NCT02227303 is a clinical study titled "A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes". The purpose of this study is to explore the effect of 8-weeks use of the Medidata Patient Cloud (a mobile application for capturing data directly from subjects, enabling entry of diary and quality of life data into internet-enabled devices) in combination with an activity tracker (Fitbit Flex) on he...

What is the current status of trial NCT02227303?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2014-08. Estimated completion is 2015-03.

What conditions does trial NCT02227303 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT02227303?

The interventions under investigation include: lifestyle modification instructional and motivational sessions (BEHAVIORAL).

Who is sponsoring clinical trial NCT02227303?

This trial is sponsored by Medidata Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02227303 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02227303's enrollment target sits among peer trials

23 108th of 130 higher than 23 of 130 other Type 2 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02227303, the US trial registry maintained by the National Library of Medicine. NCT02227303 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.